Health Care • Biotechnology: Pharmaceutical Preparations
$1.44 ▼ -0.08
(-5.26%)
MKT CAP: $12.5M • VOL: 112.1K
52W L $1 52W H $12
ROARABLE / RQD
E • 23/100
PIOTROSKI
1 / 9
LPCN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.0M | $11.2M | -$2.9M |
| YoY Revenue Growth % | -82.3% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.4M | -$1.2M | -$17.9M |
| Operating Margin % | -80.0% | -10.3% | — |
| Net Income (GAAP) | -$9.6M | $10.0K | -$16.4M |
| EBITDA (Normalized) | — | -$1.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.8M | -$1.2M | -$11.9M |
| Capital Expenditures (CapEx) | — | $90.1K | — |
| Free Cash Flow (FCF) | -$9.8M | -$1.3M | -$11.9M |
| FCF Margin % | -80.0% | -11.7% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -6.2% | — |
| Cash & Short-Term Equivalents | $5.2M | $6.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $14.5M | $21.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LPCN.